Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 1—January 2017

CME ACTIVITY - Research

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010

CME Logo

This activity has been planned and implemented through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate.

Release date: December 15, 2016; Expiration date: December 15, 2017

Learning Objectives

Upon completion of this activity, participants will be able to:

1. Assess recommendations for the management of systemic anthrax and the use of anthrax immune globulin intravenous (AIG-IV)

2. Distinguish variables associated with the application of AIG-IV in the current study

3. Assess outcomes of patients treated with AIG-IV in the current study

4. Evaluate the efficacy of AIG-IV in the current study

CME Editor

Karen L. Foster, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Karen L. Foster has disclosed no relevant financial relationships.

CME Author

Charles P. Vega, MD, Clinical Professor of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed the following financial relationships: served as an advisor or consultant for Allergan, Inc.; McNeil Consumer Healthcare; served as a speaker or a member of a speakers bureau for Shire Pharmaceuticals.

Authors

Disclosures: Xizhong Cui, MD, PhD; Leisha D. Nolen, MD, PhD; Junfeng Sun, PhD; Malcolm Booth, MB ChB, FRCA, MPhil, FFICM; Lindsay Donaldson, MB ChB, FRCA, FFICM, FRCP; Conrad P. Quinn, PhD; Anne E. Boyer, PhD; Katherine Hendricks, MD, MPH&TM; Sean Shadomy, DVM, MPH, Diplomate ACVPM; Pieter Bothma, MB ChB M. Med, FCA(SA); Owen Judd, BM BS, FRCS, FRSA; Paul McConnell, MB ChB, FRCA, EDIC, FFICM; William A. Bower, MD; and Peter Q. Eichacker, MD, have disclosed no relevant financial relationships.

>

Article Navigation

TOP